Company AnnouncementTopline results from Phase 3 EPCORE® DLBCL-4 evaluating epcoritamab in combination with lenalidomide demonstrated ...
SurvivorNet on MSN
For high-risk lymphoma, adding targeted drugs tafasitamab and lenalidomide to standard treatment keeps cancer away for longer
The frontMIND study adds two immune‑based medicines (tafasitamab and lenalidomide) to standard R‑CHOP, a type of chemotherapy, which helped patients stay in remission longer, reducing the risk of the ...
"We found that older age, early relapse, and noncurative treatments were significantly associated with inferior outcomes at a population level." — Inna Y. Gong, MD, PhD, hematologist in the Division ...
Diffuse large B-cell lymphoma (DLBCL) is a neoplasm of large B-lymphocytes that accounts for 25–30% of B-cell non-Hodgkin lymphomas. It is the most common lymphoma subtype in western countries and ...
Breast lymphomas, though rare, present a unique spectrum of clinical and pathological characteristics. This multicenter retrospective study evaluates 92 cases from four international institutions over ...
Around 30% to 40% of people with diffuse large B-cell lymphoma (DLBCL) experience a relapse after remission, and 83% of those who relapse have symptoms. Relapse symptoms can be the same as those that ...
Lymph nodes are key control centers in the immune system and play an important role in defending the body against infections and tumors. For these processes to function properly, immune cells (B cells ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results